---
layout: post
title: "Decentralized Clinical Trials for Drugs, Biological Products, and Devices; Draft Guidance for Industry, Investigators, and Other Stakeholders; Availability"
date: 2026-02-05 18:55:25 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-09399
original_published: 2023-05-03 00:00:00 +0000
significance: 8.00
---

# Decentralized Clinical Trials for Drugs, Biological Products, and Devices; Draft Guidance for Industry, Investigators, and Other Stakeholders; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** May 03, 2023 00:00 UTC
**Document Number:** 2023-09399

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled "Decentralized Clinical Trials for Drugs, Biological Products, and Devices." This draft guidance provides recommendations for sponsors, investigators, and other stakeholders regarding the implementation of decentralized clinical trials (DCTs) for drugs, biological products, and devices. In this draft guidance, a DCT refers to a clinical trial where some or all of the trial-related activities occur at locations other than traditional clinical trial sites.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/05/03/2023-09399/decentralized-clinical-trials-for-drugs-biological-products-and-devices-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-09399

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
